The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
The firm anticipates that it will soon launch the device as an in vitro diagnostic tool for analyzing tissue biopsies during surgeries in European hospitals.
Chembio said it will receive funding to develop a test that combines its Dual Path Platform (DPP) technology with a Perseus concussion biomarker.
Ohio State researchers found in a preliminary study that spectroscopy detected fibromyalgia and differentiated the condition from similar ailments.
A consortium has developed a prototype device consisting of nanosensors that measure volatile organic compounds from a breath sample.
The mass spec-based assay can detect viral proteins eight days after the onset of symptoms, compared to four to five days with PCR tests, its developers said.
In a study involving 250 military veterans, researchers have reported identifying and testing gene expression biomarkers whose levels rise with human stress.
The firms will focus on developing and implementing biomarker-based immunoassay diagnostics for kidney injury.
With deep learning software running on a supercomputer, Paige.AI is developing pathology technology that learns from large-scale digital image datasets.
Along with WHO, Mologic, and Leiden University Medical Center, FIND is developing two rapid diagnostic tests to detect circulating anodic antigen in blood or urine.